Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED will showcase new and updated clinical data for several of its internally discovered oncology drugs at the 2026 ASCO Annual Meeting in Chicago, underscoring the breadth of its late-stage pipeline. The centerpiece is a pivotal Phase II registration study of savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma in China, which met its primary objective response endpoint and supported a priority-reviewed new drug application with Chinese regulators.
Additional presentations will provide further analyses of the fruquintinib FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 trials, alongside numerous investigator-initiated studies of fruquintinib and surufatinib across colorectal, gastric, renal, gynecologic, hepatobiliary and other cancers. The extensive ASCO presence highlights HUTCHMED’s strategy to expand indications, explore combination regimens, and strengthen its competitive position in global oncology, potentially broadening treatment options and future revenue streams if these programs progress successfully.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies, particularly for oncology indications. The company develops small-molecule drugs such as savolitinib, fruquintinib and surufatinib, with a strong presence in gastrointestinal and other solid tumors and an emphasis on both China and global markets.
See more data about 0013 stock on TipRanks’ Stock Analysis page.